<DOC>
	<DOCNO>NCT01296204</DOCNO>
	<brief_summary>The first step protocol call step pre-treatment study biodistribution pharmacokinetics tracer dose radiolabeled antibody . The second step call step therapy study toxicity antitumor effect antibody B-B4 couple increase dos iodine 131 . At least 17 patient include estimate duration 2 year determine maximum tolerate dose dose limit toxicity . The immediate side effect , medium long term analyze . After determine toxic dose limit , patient treat maximum tolerated dose , total 15 patient level , measure objective tumor response treatment . These patient follow 1 year injection therapy . ÉcouterLire phonétiquement</brief_summary>
	<brief_title>Radioimmunotherapy ( RIT ) MULTIPLE MYELOMA Using Antibody B-B4 Radiolabelled With IODE 131</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<criteria>Patients confirm diagnosis multiple myeloma ( &gt; 10 % plasma cell previous myelogram ) Secretion monoclonal immunoglobulin No myelodysplasia evaluate myelogram Disease refractory relapse least 3 line therapy Patients date signed consent form Collection autologous peripheral blood stem cell contain least 2 . 106 CD 34 + cell / kg Age &gt; 18 year Performance status &lt; 2 ( see Annex I ) , life expectancy 3 month No chemotherapy radiotherapy within 4 week inclusion No major surgery within 4 week precede assessment inclusion No bisphosphonates within 2 week prior radioimmunotherapy , except treatment start three month ago . Normality biological assessment : Creatinine le equal 1.5 time normal laboratory Liver : less equal 1.5 time normal laboratory ( free conjugate bilirubin , SGOT , SGPT , gamma GT PAL ) Hemoglobin ≥ 8 g/mm3 ≥ 3 WBC 000/mm3 Neutrophils ≥ 1 500/mm3 Platelets ≥ 100 000/mm3 Patients cancer except uterine carcinoma situ basal cell skin carcinoma Patients ( ) condition ( ) Severe ( ) prevent tolerance study conduct study completion Patient pregnant unwilling take contraceptive treatment three month treatment Collection peripheral blood stem cell contain less 2106 CD 34 + cell / kg Patients enrol another experimental treatment protocol Patients already receive treatment radioimmunotherapy Myelodysplasia assess myelogram Patient thyroid Patient unable sign inform consent ÉcouterLire phonétiquement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>